(Q37515433)

20 August 2017

1 reference

title

Emerging drugs for acute graft-versus-host disease (English)

1 reference

20 August 2017

Yasser Khaled

1

1 reference

20 August 2017

Pavan Reddy

series ordinal

2

1 reference

20 August 2017

Oleg Krijanovski

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Emerging Drugs

20 August 2017

1 reference

20 August 2017

14

1 reference

20 August 2017

2

1 reference

20 August 2017

219-232

1 reference

Immunobiology of allogeneic hematopoietic stem cell transplantation

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Pathophysiology of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Role of adhesion molecules in activation signaling in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Host-reactive CD8+ memory stem cells in graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Cytolytic pathways in haematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Leukocyte migration and graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Non-HLA immunogenetics in hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Cyclophosphamide-induced immunological tolerance: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Allogeneic transplantation of CD34+ selected hematopoietic cells--clinical problems and current challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

How I treat refractory acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Steroid-refractory graft-vs.-host disease: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Infliximab for steroid‐refractory acute GVHD: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Pentostatin in steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Pluripotency of mesenchymal stem cells derived from adult marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Multilineage potential of adult human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Potential mechanisms of photopheresis in hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903018891

10.1517/14728210903018891

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference